TSH Biopharm Corporation Company Description

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan.

The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others.

It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patients with advanced solid cancers; AlphaLiquid HRR, AlphaSolid, and AlphaSolid HRR, a tissue biopsy test designed for patients with advanced solid cancers; UNITED which detects clinically-relevant genomic alterations in both DNA and RNA including microsatellite instability(MSI) and tumor mutational burden (TMB) biomarkers from FFPE tissue; Progsigna, a test for breast cancer test; and lung cancer panel.

The company was founded in 1999 and is headquartered in Taipei, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.